113 related articles for article (PubMed ID: 21571620)
1. A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.
Messori A; Fadda V; Trippoli S
J Chemother; 2011 Apr; 23(2):67-70. PubMed ID: 21571620
[TBL] [Abstract][Full Text] [Related]
2. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
3. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
[TBL] [Abstract][Full Text] [Related]
4. [Public financing for off-label use of drugs].
Hammerman A; Lipschitz Y; Pliskin J; Greenberg D
Harefuah; 2011 Feb; 150(2):163-7, 204. PubMed ID: 22164947
[TBL] [Abstract][Full Text] [Related]
5. Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.
Mellor JD; Van Koeverden P; Yip SW; Thakerar A; Kirsa SW; Michael M
Intern Med J; 2012 Nov; 42(11):1224-9. PubMed ID: 22372936
[TBL] [Abstract][Full Text] [Related]
6. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
Salvo I; Landoni G; Mucchetti M; Cabrini L; Pani L
Paediatr Anaesth; 2014 Jun; 24(6):625-31. PubMed ID: 24796404
[TBL] [Abstract][Full Text] [Related]
7. Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.
Lerose R; Musto P; Aieta M; Papa C; Tartarone A
Eur J Clin Pharmacol; 2012 May; 68(5):505-12. PubMed ID: 22166932
[TBL] [Abstract][Full Text] [Related]
8. Early market access for unauthorized drugs in Italy: The value-based price for reimbursement decisions.
Maratea D; Venturini F
Eur J Intern Med; 2016 May; 30():e15-e16. PubMed ID: 26851984
[No Abstract] [Full Text] [Related]
9. Reimbursement policies constrain the practice of oncology.
Laetz T; Silberman G
JAMA; 1991 Dec; 266(21):2996-9. PubMed ID: 1820471
[TBL] [Abstract][Full Text] [Related]
10. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands.
Franken MG; van Gils CW; Gaultney JG; Delwel GO; Goettsch W; Huijgens PC; Steenhoek A; Punt CJ; Koopman M; Redekop WK; Uyl-de Groot CA
Eur J Cancer; 2013 Jan; 49(1):8-16. PubMed ID: 22809557
[TBL] [Abstract][Full Text] [Related]
11. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
McCullagh L; Schmitz S; Barry M; Walsh C
Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
[TBL] [Abstract][Full Text] [Related]
12. [Off-label use of oncology drugs: national survey results].
González-Haba Peña E; Agustín Ferrández MJ; Mangues Bafalluy I; Alfredo López N; Fraga Fuentes MD; Marín Gil R; Martínez Bautista MJ; Clopés Estela A
Farm Hosp; 2015 Sep; 39(5):275-87. PubMed ID: 26546940
[TBL] [Abstract][Full Text] [Related]
13. The ethics of off-label use of drugs: oncology pharmacy in Italy.
Bernardi A; Pegoraro R
J Clin Pharm Ther; 2008 Apr; 33(2):95-9. PubMed ID: 18315773
[TBL] [Abstract][Full Text] [Related]
14. Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis.
Seidenschnur KEK; Dressler C; Weller K; Nast A; Werner RN
J Dtsch Dermatol Ges; 2017 Nov; 15(11):1103-1109. PubMed ID: 29064628
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of anticancer drugs.
Levêque D
Lancet Oncol; 2008 Nov; 9(11):1102-7. PubMed ID: 19012859
[TBL] [Abstract][Full Text] [Related]
16. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
Kocs D; Fendrick AM
Am J Manag Care; 2003 May; 9(5):393-400; quiz 401-2. PubMed ID: 12744301
[TBL] [Abstract][Full Text] [Related]
17. Public Reimbursement of Prescription Drugs Used For Off-Label Indications in Ontario.
Rawson N; Chhabra A
J Popul Ther Clin Pharmacol; 2018 Sep; 25(2):e23-e30. PubMed ID: 30725540
[TBL] [Abstract][Full Text] [Related]
18. Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016.
Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
Health Policy; 2019 Aug; 123(8):713-720. PubMed ID: 31277882
[TBL] [Abstract][Full Text] [Related]
19. [ProMoFIA_Oncologic: monitoring project of the innovative oncology drugs in Abruzzo].
Belfiglio M; Sichetti D; Romero M; Orsini A;
Recenti Prog Med; 2013 Jun; 104(6):241-5. PubMed ID: 23801227
[TBL] [Abstract][Full Text] [Related]
20. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
